Literature DB >> 15632004

IL-9 protects against bleomycin-induced lung injury: involvement of prostaglandins.

Mohammed Arras1, Jamila Louahed, Jean-François Heilier, Monique Delos, Frank Brombacher, Jean-Christophe Renauld, Dominique Lison, François Huaux.   

Abstract

IL-9 is a Th2 cytokine that exerts pleiotropic activities, and might be involved in the regulation of lung inflammatory processes. To characterize the activity of IL-9 on lung injury, we compared the pulmonary responses to bleomycin (blm) in IL-9 transgenic (Tg5) and wild-type (FVB) mice. Following intratracheal instillation of lethal doses of blm, the mortality rate was markedly reduced in Tg5 mice compared to their wild-type counterparts (ie, 25% mortality for Tg5 versus 85% for FVB mice, 21 days after instillation of 0.05U blm/mouse). Histological and biochemical analyses showed that blm induced less lung injury and less epithelial damage in Tg5 as compared to FVB animals. This protection of Tg5 mice was accompanied by an expansion of eosinophils and B cells in the lungs. In addition, TGF-beta and prostaglandin-E2 (PGE2) levels in broncho-alveolar lavage fluid were also increased in transgenic mice. The contribution of B cells and eosinophils to the protective mechanism did not appear essential since eosinophil-deficient (IL-5 KO) and B-deficient (muMT) mice overexpressing IL-9 were also resistant to high doses of blm. We could rule out that TGF-beta was a key factor in the protective effect of IL-9 by blocking this mediator with neutralizing antibodies. Indomethacin treatment, which inhibited PGE2 production in both strains, suppressed the protection in Tg5 mice, supporting the idea that IL-9 controls blm-induced lung injury through a prostaglandin-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15632004      PMCID: PMC1602305          DOI: 10.1016/S0002-9440(10)62236-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  59 in total

1.  IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10.

Authors:  U Grohmann; J Van Snick; F Campanile; S Silla; A Giampietri; Carmine Vacca; J C Renauld; M C Fioretti; P Puccetti
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

Review 2.  Role of transforming growth factor beta in human disease.

Authors:  G C Blobe; W P Schiemann; H F Lodish
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

3.  Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice.

Authors:  A Nakao; M Fujii; R Matsumura; K Kumano; Y Saito; K Miyazono; I Iwamoto
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

4.  Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma.

Authors:  L L McCormick; Y Zhang; E Tootell; A C Gilliam
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

5.  Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo.

Authors:  T Arai; K Abe; H Matsuoka; M Yoshida; M Mori; S Goya; H Kida; K Nishino; T Osaki; I Tachibana; Y Kaneda; S Hayashi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-05       Impact factor: 5.464

6.  A comparison of lymphocyte populations in lung tissue and in bronchoalveolar lavage fluid of rats at various times during the development of bleomycin-induced pulmonary fibrosis.

Authors:  R S Thrall; R W Barton
Journal:  Am Rev Respir Dis       Date:  1984-02

7.  Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin.

Authors:  R S Thrall; J R McCormick; R M Jack; R A McReynolds; P A Ward
Journal:  Am J Pathol       Date:  1979-04       Impact factor: 4.307

8.  The effects of the nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation.

Authors:  D J Schrier; S H Phan; B M McGarry
Journal:  Am Rev Respir Dis       Date:  1983-05

9.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

Authors:  J Van Snick; S Cayphas; A Vink; C Uyttenhove; P G Coulie; M R Rubira; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

10.  Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.

Authors:  P F Piguet; M A Collart; G E Grau; Y Kapanci; P Vassalli
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more
  9 in total

1.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

2.  Lymphatic Proliferation Ameliorates Pulmonary Fibrosis after Lung Injury.

Authors:  Peter Baluk; Ram P Naikawadi; Shineui Kim; Felipe Rodriguez; Dongwon Choi; Young-Kwon Hong; Paul J Wolters; Donald M McDonald
Journal:  Am J Pathol       Date:  2020-10-08       Impact factor: 4.307

3.  CD36, but not G2A, modulates efferocytosis, inflammation, and fibrosis following bleomycin-induced lung injury.

Authors:  Brian W Parks; Leland L Black; Kurt A Zimmerman; Allison E Metz; Chad Steele; Joanne E Murphy-Ullrich; Janusz H Kabarowski
Journal:  J Lipid Res       Date:  2013-02-06       Impact factor: 5.922

Review 4.  The unique features of Th9 cells and their products.

Authors:  Cuiyan Tan; Igal Gery
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

Review 5.  Role of interleukins in the pathogenesis of pulmonary fibrosis.

Authors:  Yi Xin She; Qing Yang Yu; Xiao Xiao Tang
Journal:  Cell Death Discov       Date:  2021-03-15

Review 6.  Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis.

Authors:  Jincheng Wang; Kaili Hu; Xuanyan Cai; Bo Yang; Qiaojun He; Jiajia Wang; Qinjie Weng
Journal:  Acta Pharm Sin B       Date:  2021-07-29       Impact factor: 11.413

7.  Deleterious Role of Th9 Cells in Pulmonary Fibrosis.

Authors:  Kui Miao Deng; Xiang Sheng Yang; Qun Luo; Yi Xin She; Qing Yang Yu; Xiao Xiao Tang
Journal:  Cells       Date:  2021-11-17       Impact factor: 6.600

8.  Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis.

Authors:  Takeshi Kobayashi; Kensuke Tanaka; Tetsuo Fujita; Hiroki Umezawa; Hiroyuki Amano; Kento Yoshioka; Yusuke Naito; Masahiko Hatano; Sadao Kimura; Koichiro Tatsumi; Yoshitoshi Kasuya
Journal:  Respir Res       Date:  2015-08-20

Review 9.  The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis.

Authors:  Siavash Bolourani; Max Brenner; Ping Wang
Journal:  J Mol Med (Berl)       Date:  2021-07-13       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.